Editor’s Note August 29, 2012
This week’s Sentinel features a series of new columns exploring social media, hot stocks and sectors, and upcoming events that could move your investment portfolio. […]
News
MediTech Strategic Consultants B.V.: European Medical Devices Market Authorization (CE MARK)
MediTech Strategic Consultants B.V. (MediTech) is full service European Contract Research Organization (CRO) specializing in medical devices and combination products focused on Clinical, Regulatory and Quality consulting as well as Authorized Representative Services.
Your Biotech Calendar, August 28: PDUFA Dates, SEC Filings, Financings
At OneMedPlace, our goal is to be your eyes and ears to the biotech and life sciences sector: putting into perspective what we’ve seen so far, and providing you with snapshots of and what’s upcoming.
2012 BDO IPO Halftime Report: Current Market Trends
As Ryan Starkes, Partner and a Practice Leader within BDO’s Technology and Life Sciences Industry Group informs us, BDO is interested in emerging growth life science companies particularly those planning on exploring international development. All companies looking to utilize the capital markets in the U.S., including those in the life sciences industry, have always had to navigate particularly perplexing regulatory requirements.
Hashtag Biotech: Where to Find Investors on Twitter
“Hashtag Biotech” is a new weekly column in which OneMedPlace explores the power of Twitter and other social media tools in facilitating emerging growth company development. This week, we identify the most intriguing biotech investors using Twitter.
The Briefing Room, August 24: The Week That Was in Microcap Biotech Stocks
OneMedPlace introduces a new series, “The Briefing Room”, capturing the past week’s most important developments in microcap life sciences indexes. This week, we feature Star Scientific, Kips Bay Medical, XOMA and Stellar Pharmaceuticals.
Bulls, Bears: Hot Nanocap CNS Companies
In Part II of our special report on the state of companies operating in central nervous system disease in the public markets, we look at one of the most promising nanocap companies we believe is ready to skyrocket.
Bulls, Bears: The State of CNS Companies in the Public Markets
Historically, the biotech sector has found it difficult to navigate CNS. It also has affected shareholders in numerous enterprises, with the perception that billions of investor dollars have already been wasted on overreaching and misunderstood technologies.
Release: DARPA Awards $3.8 Million Contract to CytoSorbents Corporation
Defense Advanced Research Projects Agency, or DARPA, has awarded the Company a technology development contract worth up to $3.8 million over five years as part of its Dialysis-Like Therapeutics (DLT) program to treat sepsis, pending satisfactory achievement of key milestones.
OneMedRadio: Dr. Daniel Teper of Immune Pharmaceuticals on the Power of Monoclonal Antibodies
IMMUNE Pharmaceuticals is an Israeli and US based emerging leader in the development of antibody therapeutics in cancer and inflammation. IMMUNE has multiple drug candidates based on proprietary cytotoxic formulations, linkers and monoclonal antibodies.